Takeda Pharmaceutical Co Stock Performance
| TAK Stock | USD 13.38 0.05 0.38% |
The entity has a beta of 0.0291, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Takeda Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Takeda Pharmaceutical is expected to be smaller as well. At this point, Takeda Pharmaceutical has a negative expected return of -0.13%. Please make sure to validate Takeda Pharmaceutical's potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if Takeda Pharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Takeda Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 0.43 | Five Day Return (0.32) | Year To Date Return (6.30) | Ten Year Return (36.41) | All Time Return (50.87) |
Forward Dividend Yield 0.0437 | Payout Ratio 0.01 | Forward Dividend Rate 0.58 | Dividend Date 2024-07-08 | Ex Dividend Date 2024-03-27 |
1 | Antibody Drug Conjugates Market Size Potential to Reach USD Billion by 2032 By IMIR Market Research Pvt. Ltd. | 10/07/2024 |
2 | Takeda anuncia slidos resultados del primer semestre del ejercicio fiscal 2024 y eleva sus perspectivas para el ao completo | 11/01/2024 |
3 | Results Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates | 11/04/2024 |
4 | T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and ... | 11/06/2024 |
5 | Earnings call Mirum Pharmaceuticals reports robust Q3 2024 results | 11/12/2024 |
6 | GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy Genetic Medicine Platform into Immunology | 11/13/2024 |
7 | Earnings call KORU Medical Systems reports robust Q3 growth | 11/14/2024 |
8 | Microbiomes Market to Grow by USD 1.13 Billion , Rising Disease Prevalence Driving Revenue, with AI Powering Market Evolution - Technavio | 11/19/2024 |
9 | Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform | 11/20/2024 |
10 | HUTCHMED Announces Launch by Takeda of FRUZAQLA in Japan | 11/22/2024 |
| Begin Period Cash Flow | 533.5 B |
Takeda |
Takeda Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 1,462 in Takeda Pharmaceutical Co on August 27, 2024 and sell it today you would lose (124.00) from holding Takeda Pharmaceutical Co or give up 8.48% of portfolio value over 90 days. Takeda Pharmaceutical Co is generating negative expected returns assuming volatility of 0.8721% on return distribution over 90 days investment horizon. In other words, 7% of stocks are less volatile than Takeda, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Takeda Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Takeda Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Takeda Pharmaceutical Co, and traders can use it to determine the average amount a Takeda Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1544
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TAK |
Estimated Market Risk
| 0.87 actual daily | 7 93% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Takeda Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Takeda Pharmaceutical by adding Takeda Pharmaceutical to a well-diversified portfolio.
Takeda Pharmaceutical Fundamentals Growth
Takeda Stock prices reflect investors' perceptions of the future prospects and financial health of Takeda Pharmaceutical, and Takeda Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Takeda Stock performance.
| Return On Equity | 0.0415 | ||||
| Return On Asset | 0.0278 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 69.15 B | ||||
| Shares Outstanding | 3.17 B | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 4.26 T | ||||
| Gross Profit | 2.44 T | ||||
| EBITDA | 900.33 B | ||||
| Net Income | 144.07 B | ||||
| Cash And Equivalents | 533.53 B | ||||
| Cash Per Share | 208.91 X | ||||
| Total Debt | 5.46 T | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 1.18 X | ||||
| Book Value Per Share | 4,366 X | ||||
| Cash Flow From Operations | 716.34 B | ||||
| Earnings Per Share | 0.59 X | ||||
| Market Capitalization | 42.42 B | ||||
| Total Asset | 15.11 T | ||||
| Retained Earnings | 1.39 T | ||||
| Working Capital | 245.48 B | ||||
About Takeda Pharmaceutical Performance
By examining Takeda Pharmaceutical's fundamental ratios, stakeholders can obtain critical insights into Takeda Pharmaceutical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Takeda Pharmaceutical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 212.43 | 151.22 | |
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
Things to note about Takeda Pharmaceutical performance evaluation
Checking the ongoing alerts about Takeda Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Takeda Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Takeda Pharmaceutical generated a negative expected return over the last 90 days | |
| Takeda Pharmaceutical has a strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: HUTCHMED Announces Launch by Takeda of FRUZAQLA in Japan |
- Analyzing Takeda Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Takeda Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Takeda Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Takeda Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Takeda Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Takeda Pharmaceutical's stock. These opinions can provide insight into Takeda Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.59 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.